Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Francesca Guijarro, Marc Dabad, Mònica López-Guerra, Alex Bataller Torralba, Sandra Castaño-Díez, Carlos Jimenez-Vicente, Marta Garrote, José Ramón Álamo Moreno, Marta Pratcorona, Neus Villamor, Dolors Colomer, Silvia Bea, Dolors Costa, Anna Esteve-Codina, Marina Díaz-Beyá, Jordi Esteve

Blood (2023) 142 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2023-188261

Published: 2023

Journal Articles

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Blood (2023) 142 (Supplement 1): 63.

https://doi.org/10.1182/blood-2023-185627

Published: 2023

Journal Articles

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Helena Castellet, Guillermo Ramil López, Ana Garrido, Alícia Artigas-Baleri, Marta Pratcorona, Olga Salamero, Albert Cortés-Bullich, Susana Vives, Mar Tormo, Martin Mascaro Riera, David Gallardo, Josep Maria Marti Tutusaus, Antonio Garcia, Jorge Sierra, Jordi Esteve, Josep Nomdedeu

Blood (2023) 142 (Supplement 1): 6045.

https://doi.org/10.1182/blood-2023-186064

Published: 2023

Journal Articles

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Blood (2022) 140 (Supplement 1): 11821–11823.

https://doi.org/10.1182/blood-2022-164718

Published: 2022

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

Journal Articles

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140670

Published: 2020

Journal Articles

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Giulia Maggioni, MD, Cristina Astrid Tentori, MD, Maria Teresa Voso, MD, Sonja Heibl, MD, Klaus H. Metzeler, MD, Jan Moritz Middeke, MD, Joana Desterro, Maria Carmo-Fonseca, Erica Travaglino, Paola Fazi, MD, Alfonso Piciocchi, MS, Annika Maria Dufour, PhD, Jordi Esteve, Marta Pratcorona, MD, Valentina Mancini, MD, Federico Lussana, MD, Karsten Spiekermann, Christian Thiede, MD, Friedrich Stolzel, MD, Aida Botelho de Sousa, Mar Tormo, Pamela Acha, Montserrat Arnan, Nicola Fracchiolla, MD, Marcus Hentrich, Christoph Sippel, Bernhard Heilmeier, Marcos Lemos, Albertina Nunes, Sonia Matos, Marina Diaz, Ana Garrido, MD, David Gallardo, MD, Susana Vives, MD, Olga Salamero, Elisabetta Todisco, MDPhD, Claudia Basilico, MD, Francesco Passamonti, Sigrid Machherndl-Spandl, MD, Lisa Pleyer, Jorge Sierra, Francesc Solé, PhD, Matteo Giovanni Della Porta, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-140494

Published: 2020

Journal Articles

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Blood (2019) 134 (Supplement_1): 289.

https://doi.org/10.1182/blood-2019-128682

Published: 2019

Journal Articles

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with D e Novo Mutated NPM1 (NPM1mut) a cute Myeloid Leukemia

Guadalupe Oñate, MD, Ana Garrido, MD, Jordi Esteve, MD PhD, Rosa Coll, MD, Montserrat Arnan Sangerman, MD, Susana Vives, MD, Antonia Sampol, MD PhD, Mar Tormo, MD PhD, Lourdes Escoda, MD, Maria Paz Queipo De Llano, MD, Antoni Garcia-Guiñon, MD, Joan Bargay, MD PhD, Olga Salamero, MD, Alba Aljarilla, Salut Brunet, MD PhD, Jorge Sierra, MD, Josep Nomdedeu, MD PhD, Marta Pratcorona, MD PhD

Blood (2018) 132 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2018-99-115337

Published: 2018

Journal Articles

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Blood (2018) 132 (Supplement 1): 1385.

https://doi.org/10.1182/blood-2018-99-110895

Published: 2018

Journal Articles

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Blood (2017) 130 (Supplement 1): 567.

https://doi.org/10.1182/blood.V130.Suppl_1.567.567

Published: 2017

Journal Articles

Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 5281.

https://doi.org/10.1182/blood.V128.22.5281.5281

Published: 2016

Journal Articles

Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Marta Pratcorona, Jordi Lopez-Pardo, MD, Ana Garrido, MD, Salut Brunet, MD PhD, Josep-Maria Ribera, MD PhD, Mar Tormo, MD PhD, Lourdes Escoda, MD PhD, Olga Salamero, Montserrat Arnan, MD PhD, David Gallardo, MD, Joan Bargay, MD, Montserrat Hoyos, PhD, Marina Diaz-Beya, MD PhD, Ruth M Risueño, Josep F. Nomdedeu, MD PhD, Jorge Sierra, MD PhD, Jordi Esteve, MD PhD

Blood (2015) 126 (23): 2511.

https://doi.org/10.1182/blood.V126.23.2511.2511

Published: 2015

Journal Articles

Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Blood (2015) 126 (23): 2514.

https://doi.org/10.1182/blood.V126.23.2514.2514

Published: 2015

Journal Articles

Exploring the Expression Profile of Long Non-Coding RNA (lncRNA) in Different Acute Myeloid Leukemia (AML) Subtypes: t(8;16)(p11;p13)/MYST3-Crebbp AML Harbors a Distinctive Lncrna Signature

Marina Diaz-Beya, MD PhD, Alfons Navarro, Anna Cordeiro, Marta Pratcorona, Joan Castellano, Miguel Angel Torrente, Meritxell Nomdedeu, Ruth Risueño, Maria Rozman, Mariano Monzo, Jordi Esteve, MD PhD

Blood (2015) 126 (23): 1397.

https://doi.org/10.1182/blood.V126.23.1397.1397

Published: 2015

Journal Articles

Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution

Marina Diaz-Beya, MD PhD, Miguel Angel Torrente, Alfonso Ardilla, Carles Serra, Nuria Martinez, Maria Suarez-Lledo, Carmen Martinez, Francesc Fernandez, Laura Rosiñol, Gonzalo Gutierrez, Pedro Marin, Marta Pratcorona, Nuria Mariegues, Noemi Llobet, Marta Bistagne, Enric Carreras, Alvaro Urbano-Ispizua, Montserrat Rovira, Jordi Esteve, MD PhD

Blood (2015) 126 (23): 4395.

https://doi.org/10.1182/blood.V126.23.4395.4395

Published: 2015

Journal Articles

Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group

Blood (2014) 124 (21): 3798.

https://doi.org/10.1182/blood.V124.21.3798.3798

Published: 2014

Journal Articles

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Marina Díaz-Beyá, MD PhD, Alfons Navarro, PhD, Salut Brunet, MD PhD, Josep F Nomdedeu, MD, Anna Cordeiro, Msc, Marta Pratcorona, MD PhD, Meritxell Nomdedeu, MD PhD, Ruth M Risueño, PhD, Josep-Maria Ribera, MD PhD, Mar Tormo, MDPhD, Rafael F. Duarte, MD PhD, Olga Salamero, MD, Lourdes Escoda, MD, David Gallardo, MD PhD, Carmen Pedro, MD, Josep M Marti-Tutusaus, Jorge Sierra, MD, Mariano Monzó, MD PhD, Jordi Esteve, MD PhD

Blood (2014) 124 (21): 1003.

https://doi.org/10.1182/blood.V124.21.1003.1003

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1 , FLT3 -ITD, and CEBPA : A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT

Blood (2014) 124 (21): 324.

https://doi.org/10.1182/blood.V124.21.324.324

Published: 2014

NARROW

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Ubtf tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with D e Novo Mutated NPM1 (NPM1mut) a cute Myeloid Leukemia

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years

Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012

Exploring the Expression Profile of Long Non-Coding RNA (lncRNA) in Different Acute Myeloid Leukemia (AML) Subtypes: t(8;16)(p11;p13)/MYST3-Crebbp AML Harbors a Distinctive Lncrna Signature

Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution

Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group

The LincRNA HOTAIRM1 , Located in the HOXA genomic Region , impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only